Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

被引：0
|
作者：
Bernd Tischer
Renate Huber
Matthias Kraemer
Mario E. Lacouture
机构：
[1] Kantar Health,Dermatology Service, Department of Medicine
[2] Merck KGgA,undefined
[3] Memorial Sloan Kettering Cancer Center,undefined
来源：
Supportive Care in Cancer | 2017年 / 25卷
关键词：
Dermatologic adverse events; EGFR inhibitors; Health-related quality of life; Skin rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：651 / 660
页数：9
相关论文
共 50 条
  • [1] Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
    Tischer, Bernd
    Huber, Renate
    Kraemer, Matthias
    Lacouture, Mario E.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (02) : 651 - 660
  • [2] Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors.
    Gu, Stephanie
    Dusza, Stephen W.
    Dunkel, Ira J.
    Drilon, Alexander E.
    Lacouture, Mario E.
    Markova, Alina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Management of EGFR TKI-induced dermatologic adverse events
    Melosky, B.
    Leighl, N. B.
    Rothenstein, J.
    Sangha, R.
    Stewart, D.
    Papp, K.
    CURRENT ONCOLOGY, 2015, 22 (02) : 123 - 132
  • [4] Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors
    Wu, Peggy A.
    Balagula, Yevgeniy
    Lacouture, Mario E.
    Anadkat, Milan J.
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (04) : 343 - 351
  • [5] Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
    Lorusso, Patricia
    ONCOLOGY-NEW YORK, 2009, 23 (02): : 186 - 194
  • [6] Dermatologic adverse events in EGFR-TKIs: A real-world analysis
    Paton, Emily
    Friedman, Ryan Jeremy
    Cetnar, Jeremy Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] DERMATOLOGIC ADVERSE EVENTS OF BCR-ABL TYROSINE KINASE INHIBITORS
    Shatokhina, E. A.
    Turkina, A. G.
    Kruglova, L. S.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2020, 65 (02): : 154 - 173
  • [8] Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know
    Habre, Maya
    Habre, Samer Bassilios
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2016, 8 (12) : 1437 - 1446
  • [9] Dermatologic immune-related adverse events to checkpoint inhibitors in cancer
    Shah, Neil J.
    Lacouture, Mario E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : 407 - 409
  • [10] Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab
    Choi, Jennifer Nam
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2014, 33 (01) : 40 - 48
12345